Barely Significant
← all excerpts

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.

Ann Rheum Dis · 2012 · PMC3372319 · PMID 22121129

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

highly significantno p-value reported
4 5 Similar reasoning may be applied to explain the highly significant difference in radiographic progression observed between placebo + MTX and golimumab + MTX despite only an intermediary level of baseline inflammation compared with previously conducted trials of golimumab. 4 5 16 Finally, more patients met the EE criteria in the golimumab 50 mg + MTX group (Group 2) than in the golimumab 100 mg + MTX group (Group 3), indicating the potential for a dose response.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.